Jane Street’s Strategic Trust Kelly CRISPR & Gene Editing Technology ETF XDNA Stock Holding History

Jane Street’s Portfolio XDNA Stock Details XDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,486	Closed	-$92.6K	–	10032
2023 Q3	$92.6K	Buy	+12,486	New	+$108K	﹤0.01%	7982
2022 Q4	–	Sell	-101,588	Closed	-$1.19M	–	10456
2022 Q3	$1.19M	Buy	101,588 +74,210	+271%	+$939K	﹤0.01%	5108
2022 Q2	$279K	Sell	27,378 -47,691	-64%	-$495K	﹤0.01%	7730
2022 Q1	$943K	Buy	+75,069	New	+$971K	﹤0.01%	6263

Jane Street's XDNA Position: Q4 2023 in Review

Jane Street sold out of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) in Q4 2023, closing a stake of 12,486 shares — an estimated $92.6K sold.

Jane Street first reported a position in XDNA in Q1 2022 and held it in 4 quarters. The position peaked at $1.19M in Q3 2022. 0 funds tracked by Wall St. Rank hold XDNA as of Q4 2023.

Jane Street reported no remaining Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position as of Q4 2023 after selling out during the quarter.
Jane Street sold 12,486 Strategic Trust Kelly CRISPR & Gene Editing Technology ETF shares in Q4 2023, an estimated $92.6K.
Jane Street first reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in Q1 2022 and held it in 4 quarters.
Jane Street's Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position peaked at $1.19M in Q3 2022.
0 funds tracked by Wall St. Rank held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF as of Q4 2023.

Based on Jane Street's 13F filing for Q4 2023, filed 15 Feb 2024.